AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04607239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: * A weekly telephone call by the CRA for the collection of home blood pressure measurements (which the patient measures twice a day everyday), for therapeutic education, and for treatment compliance assessment.~* A monthly call by the attending physician for treatment titration and side effects check.
Study NCT04607239 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Usual Care without Telemonitoring
Description: * Attending the follow up visits after inclusion at Day 90 (D-90) \& Day 180 (D-180) for face to face consultation with the attending physician.~* Usual care without any phone calls for therapeutic education, treatment compliance assessment, treatment titration or side effects check.
Study NCT00041509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-424323
Description: 500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days
Study NCT00041509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo, oral, BID for 28 days
Study NCT04122430 — intervention group
Intervention type: OTHER
Intervention: Review of Health Information
Study NCT01134523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin, CTX, Paclitaxel
Description: Epirubicin 90mg/m2 and CTX 600mg/m2 on day1 of each 21-day cycle, 4 cycles; followed by Paclitaxel 175mg/m2 on day1 of each 21-day cycle, 4 cycles.
Study NCT01134523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin, Paclitaxel
Description: Epirubicin 75mg/m2 on day1 and Paclitaxel 175mg/m2 on day2 of each 21-day cycle, 6 cycles.
Study NCT03832179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab
Study NCT03832179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab
Study NCT03832179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept
Study NCT03832179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozurdex
Description: Ozurdex
Study NCT03288766 — intervention group
Intervention type: PROCEDURE
Intervention: PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software
Description: The SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) is an FDA-cleared fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology, indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients without any alterations of cardiac rhythms that change the normal presentation of the P-wave. A software package, MODUS II, has been developed to accurately analyze the entire ECG complex and identify the correct placement of the PICC tip based on a patient's individual ECG, in the absence of an easily identifiable P-wave. This software system is designed to provide visual and/or audio cues to notify the PICC placer of the location of the PICC tip relative to the cavoatrial junction (CAJ) of the patient.
Study NCT02475083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Rehabilitation with virtual reality, using Football games, Boxe, Bambolê and Tennis.
Study NCT02475083 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Stretching exercises in limbs, trunk mobilization in the three planes, balance training in standing position, training of balance reactions and gait training.
Study NCT02475083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional
Description: Stretching exercises in limbs, trunk mobilization in the three planes, balance training in standing position, training of balance reactions and gait training.
Study NCT01840371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional sedation
Description: Propofol Meperidine : 25 mg IV just before procedure~* IV bolus of 1 mg/kg for sedation induction,~* Infusion of 60 mcg/min/kg for maintenance of sedation~* Additional bolus dose of 10mg as needed for adequate sedation
Study NCT01840371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental sedation
Description: Fentanyl~* IV bolus of 1 µg/kg for sedation induction~* Additional bolus dose of 0.5 µg/kg as needed for adequate pain control Propofol~* IV bolus of 0.4 mg/kg for sedation induction~* Infusion of 30 µg/min/kg for maintenance of sedation~* Additional bolus dose of 10mg as needed for adequate depth of sedation
Study NCT02324465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: King Vision Video Laryngoscope
Description: Intubation via King Vision Video Laryngoscope
Study NCT02324465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope Video Laryngoscope
Description: Intubation via Glidescope Video Laryngoscope
Study NCT02456948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 6 weeks 200mg/day Minocycline add-on
Study NCT02456948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 weeks Placebo add-on
Study NCT03160677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure target < 130 mm Hg
Description: Adaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 130 mm Hg
Study NCT03160677 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systolic blood pressure target < 185 mm Hg
Description: Adaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 185 mm Hg
Study NCT00414531 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: 20 to 80 mg per day
Study NCT02356471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Management of Therapy Complications Fitbit Zip (portable pedometer device)
Description: Use pedometer to monitor physical activity
Study NCT02356471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02356471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03411005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metabolic availability of lysine in sorghum
Description: Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from sorghum and 1 level from sorghum with lentils.
Study NCT02698800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue blocking (BB) lenses
Description: Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime.
Study NCT02698800 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Clear lenses
Description: Participants will wear clear lenses each night for 1 week for 2 hours preceding bedtime.
Study NCT03219398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumoperitoneum pressure
Description: Subjects were set to 8- 10 mmHg pressure during laparoscopic surgery; Subjects were set to 12-14 mmHg pressure during laparoscopic surgery
Study NCT01512043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing control
Description: Practice of device guided breathing control twice a day for four weeks.
Study NCT01512043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing control
Description: Practice of device guided breathing control twice a day for four weeks.
Study NCT01512043 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Breathing control
Description: Practice of device guided breathing control twice a day for four weeks.
Study NCT01755858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendavia
Study NCT01755858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01902680 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Focal brachytherapy
Description: Focal brachytherapy with permanent I125 localized implant.
Study NCT02651441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 IV on day1 and day8, repeat every 3 weeks.
Study NCT02651441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 IV on day1 and day8, repeat every 3 weeks.
Study NCT02651441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
Study NCT02651441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
Study NCT02651441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-CIK
Description: 8×10\^9 D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
Study NCT01188746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: McGill Quality of Life Questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire
Description: Participants will be interviewed twice (if they chose to participate in the qualitative portion) and complete instruments at three time points: 1) immediately prior to the procedure, 2)within seven days after the procedure, preferably prior to discharge, and 3) three weeks after their catheter placement.
Study NCT02771015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Border®
Description: randomization
Study NCT02771015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cosmopor steril®
Description: randomization
Study NCT03455166 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum Markers
Description: Serum Markers
Study NCT01274364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JADE
Description: Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
Study NCT01274364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIAMOND
Description: Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
Study NCT00534703 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: AAV1/SERCA2a
Description: AAV1/SERCA2a will be delivered by a percutaneous method in the catheter laboratory. Dose: 1x 10\^13 DRP (DNase resistant particles)
Study NCT00534703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo aliquots will be of the same composition as the investigational medicinal product with the absence of the active ingredient and will be visually indistinguishable from the medicinal product. Placebo is prepared and handled exactly as above in a blinded fashion.
Study NCT04141033 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: assessment of neopterin levels
Description: neopterin is a macrophage biomarker used for diagnosis of active periodontitis and the response to treatment
Study NCT01890239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Programme for the Last Days of Life
Description: The Care Programme essentially aims to raise awareness among geriatric health care staff of the importance for improving end-of-life care and to prepare them for a change in end-of-life care, to train staff in delivering good end-of-life care with the support of a multi-professional document called the Care Guide for the Last Days of Life, to support dying geriatric patients with the Care Guide for the Last days of Life, to regularly evaluate the delivered end-of-life care and support and to further educate the staff in delivering optimal end-of-life care. The Care Programme consists of the following documents: (1) the Care Guide for the Last Days of Life, (2) supportive documentation and (3) an implementation guide.
Study NCT03659409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention
Description: 4 weekly 2-hour sessions. Participants will be introduced, taught and guided in practice of mindfulness-based interventions that are focused on their (1) breath, (2) senses, (3) body and bodily movements, (4) feelings of empathy and compassion.
Study NCT03659409 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist - Mindfulness-Based Intervention
Description: Participants in this group will only receive the Mindfulness-Based Intervention 3-months after they have started the study and baseline measurements. While participants in the Intervention Arm are receiving the treatment, this group will receive No intervention for the first four weeks and will continue as treatment as usual until it is their turn to receive the Intervention.
Study NCT04060368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Sleeve Gastroplasty (ESG) with OverStitch® system + Lifestyle modifications
Description: Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
Study NCT04060368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Sleeve Gastrectomy (LSG) + Lifestyle modifications
Description: Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
Study NCT02841774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: 40mg daily (Weeks 2 - 14)
Study NCT02841774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20mg daily (Weeks 2 - 14); at Week 6, if AST, AST, and CK \<+1.5 x ULN, and LDL-c is >60 and decreased by less than 25% compared with week 2, then dose will be increased to rosuvastatin 40mg daily
Study NCT04172363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octenisept and Serasept
Description: Swab probes of wounds will be taken upon study inclusion and analysed for resistance on Octenisept and Serasept. If the patient indicates resistance on one of the antiseptics, he/she will receive the other antiseptic for wound dressings
Study NCT04462263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0014242
Description: Solid suspension capsule
Study NCT03577626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: Hemay005 tablets will be taken orally in dose of 52.5mg at fasted dosing on period one followed by fed dosing on period two.
Study NCT03577626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: Hemay005 tablets will be taken orally in dose of 52.5mg at fed dosing on period one followed by fasted dosing on period two
Study NCT04469153 — intervention group
Intervention type: OTHER
Intervention: No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests
Description: No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests
Study NCT01923077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: usual care with Simvastatin
Study NCT01923077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: rosuvastatin 80 mg as loading dose at randomization followed by rosuvastatin 40 mg daily.
Study NCT01882140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation by Capacitive Field
Study NCT01882140 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electrical Stimulation by Capacitive Field Placebo Sham
Study NCT00957047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eslicarbazepine acetate
Description: oral tablets
Study NCT00957047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once daily placebo comparator
Study NCT00957047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL - Part II
Description: Eslicarbazepine acetate was supplied as scored 800-mg tablets for daily oral administration.
Study NCT01271439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400mg/m2 intravenous infusion the week before radiotherapy, 250mg/m2 intravenous infusion weekly for 6 weeks during radiotherapy
Study NCT03703063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered by intravenous infusion over 30 minutes.
Study NCT03703063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: Administered by intravenous infusion over 30-40 minutes.
Study NCT03703063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onivyde
Description: Administered by intravenous infusion over 90 minutes.
Study NCT03703063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered by intravenous infusion over 30 minutes.
Study NCT03703063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fu
Description: Administered by intravenous infusion over 46 hours.
Study NCT03034226 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose clamp technique
Description: Hyperinsulinemic euglycemic and hyperinsulinemic hypoglycemic clamp procedure with infusion of insulin and glucose
Study NCT02207231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Description: 100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).
Study NCT02207231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guselkumab 100 mg
Description: 100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).
Study NCT02207231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guselkumab 100 mg
Description: 100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).
Study NCT02207231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for guselkumab
Description: Subcutaneous injections to maintain the blind.
Study NCT02207231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for guselkumab
Description: Subcutaneous injections to maintain the blind.
Study NCT02207231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for guselkumab
Description: Subcutaneous injections to maintain the blind.
Study NCT02207231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: 80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 47.
Study NCT02207231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for adalimumab
Description: Subcutaneous injections to maintain the blind.
Study NCT02207231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for adalimumab
Description: Subcutaneous injections to maintain the blind.
Study NCT03236766 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Citizens' panels
Description: This study is exploratory in nature, designed to capture lay Pacific Islanders' thoughts and beliefs about existing service engagement approaches. Therefore, there are no study arms to list.
Study NCT03929367 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: Single IV administration of oxytocin
Study NCT01150747 — intervention group
Intervention type: DRUG
Intervention: ceftriaxone
Description: 250mg IM once
Study NCT01150747 — intervention group
Intervention type: DRUG
Intervention: Azithromycin
Description: 1 gm once
Study NCT02449876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuroscience Education
Description: The following topics will be discussed in the education~* Basic structure of the nervous system~* Basic physiology of the nervous system~* The function and importance of pain~* Strategies to lessen the impact of pain~The instruction will be delivered in an interactive manner so that questions are addressed immediately. At the conclusion of the session each subject will receive the book: Why Do I Hurt by Adriaan Louw to reinforce the information discussed in the session. Subjects will be asked to read the 50 page book prior to the second session.~Session 2:~The session will begin with a review of the topics discussed in Session 1 and contained in the book. Subject will be encouraged to ask questions and get clarification on any of the topics that are unclear.
Study NCT00552331 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plates to treat fractures of the distal femur
Description: use of dynamic condylar screws or locking condylar plates in the treatment of distal femur fractures